FGF2-Derived PeptibodyF2-MMAE Conjugate for Targeted Delivery of Cytotoxic Drugs into Cancer Cells Overexpressing FGFR1

Karolina Jendryczko, Julia Chudzian, Natalia Skinder, Łukasz Opaliński, Jakub Rzeszótko, Antoni Wiedlocha, Jacek Otlewski, Anna Szlachcic

    Research output: Contribution to journalArticleAcademicpeer-review

    41 Downloads (Pure)

    Abstract

    Fibroblast growth factor receptors (FGFRs) are emerging targets for directed cancer therapy. Presented here is a new FGFR1-targeting conjugate, the peptibodyF2, which employs peptibody, a fusion of peptide and the Fc fragment of human IgG as a selective targeting agent and drug carrier. Short peptide based on FGF2 sequence was used to construct a FGFR1-targeting peptibody. We have shown that this peptide ensures specific delivery of peptibodyF2 into FGFR1-expressing cells. In order to use peptibodyF2 as a delivery vehicle for cytotoxic drugs, we have conjugated it with MMAE, a drug widely used in antibody-drug conjugates for targeted therapy. Resulting conjugate shows high and specific cytotoxicity towards FGFR1-positive cells, i.e., squamous cell lung carcinoma NCI-H520, while remaining non-toxic for FGFR1-negative cells. Such peptibody-drug conjugate can serve as a basis for development of therapy for tumors with overexpressed or malfunctioning FGFRs.

    Original languageEnglish
    Article number12102992
    Number of pages17
    JournalCancers
    Volume12
    Issue number10
    DOIs
    Publication statusPublished - 15-Oct-2020

    Cite this